Skip to content

Evaluation of the Population-level Impact of PMTCT Option B+ in Zimbabwe

Evaluation of the Population-level Impact of Prevention of Mother-to-Child HIV Transmission Program Option B+ in Zimbabwe

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03388398
Enrollment
30642
Registered
2018-01-03
Start date
2012-01-31
Completion date
2019-01-31
Last updated
2023-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Keywords

Mother-to-child transmission of HIV (MTCT), Prevention of mother-to-child HIV transmission (PMTCT), Antiretroviral therapy (ART), Antenatal care (ANC), Pediatric infections, Pregnancy

Brief summary

This study evaluates the impact of Zimbabwe's program for the prevention of mother-to-child HIV transmission (PMTCT) on vertical transmission of HIV infection and HIV-free survival among infants exposed to HIV. The study will test the hypothesis that the accelerated PMTCT program in Zimbabwe will result in fewer new HIV infections in infants and will increase infant survival.

Detailed description

The World Health Organization (WHO) recommends that all pregnant women receive antiretroviral therapy (ART) during pregnancy and breastfeeding (Option B) or ideally throughout their lives regardless of clinical stage (Option B+). In February 2013, Zimbabwe's Ministry of Health and Child Welfare (MoHCW) declared that Zimbabwe would begin implementing Option B+ in October of 2013. This impact evaluation utilizes serial population-based, community-level surveys to comprehensively assess the prevention of mother-to-child HIV transmission strategy (PMTCT) 'Option B+' among mother-infant pairs in Zimbabwe. The investigators will assess the population-level impact of Option B+ in Zimbabwe using serial community-based cross-sectional serosurveys with data from three time points: 2012 (pre-Option A standard of care), 2014 (post-Option A / pre-Option B+), and 2017 (post Option B+ implementation) in order to monitor population-level trends in MTCT and HIV-free infant survival. The investigators will compare outcomes among infants from 2017 to outcomes among mother-infant pairs who participated in similar surveys conducted in 2012 and 2014. These community-level data, along with in-depth facility survey data, will also allow the investigators to examine impact heterogeneity by the extent of integration of PMTCT and ART services at the facility. Together with effectiveness data from the serosurveys, facility-level resource utilization and cost data will allow assessment of Option B+ cost-effectiveness. In addition, this study will also include a population-based, community-level survey conducted in 2017 to assess retention of mothers in ART services after weaning (19-36 months postpartum). These data will allow the investigators to assess HIV-infected mothers' retention in care at the time of the survey, when most mothers will have stopped breastfeeding

Interventions

None listed

Sponsors

Centre for Sexual Health and HIV/AIDS Research Zimbabwe (CeSHHAR Zimbabwe)
CollaboratorOTHER
Consorcio de Investigación sobre VIH/SIDA/TB (CISIDAT).
CollaboratorOTHER
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
CollaboratorNIH
Liverpool School of Tropical Medicine
CollaboratorOTHER
Ministry of Health and Child Welfare, Zimbabwe
CollaboratorOTHER
Elizabeth Glaser Pediatric AIDS Foundation
CollaboratorOTHER
Children's Investment Fund Foundation
CollaboratorOTHER
University of California, Berkeley
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum

Inclusion criteria

Mothers-Infant pairs: * Mother or caregiver is 16 years of age or older * Delivered or provides care for an infant (alive or deceased) who is or who would have been 9-18 months of age at the time of the survey * Able and willing to provide written informed consent

Exclusion criteria

Mothers-Infant pairs: * Mother or caregiver is younger than 16 years of age * Infant (alive or deceased) is not/would not have been 9-18 months of age at the time of the survey Inclusion Criteria Mothers/Caregivers: * At least 16 years of age or older * Delivered an infant (alive or deceased) who is or who would have been 19-36 months of age at the time of the survey * Able and willing to provide written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Vertical transmission of HIV infection9-18 months after birthProportion of infants born to HIV-infected mothers who were HIV-infected
HIV-free survival among infants exposed to HIV9-18 months after birthProportion of infants born to HIV-infected mothers who were alive and HIV-uninfected

Secondary

MeasureTime frameDescription
Retention of mothers in antiretroviral therapy services (ART) services after weaning19-36 months postpartumThe proportion of HIV-infected mothers who were initiated on ART and who continued ART after weaning
Time between weaning and discontinuation of antiretroviral therapy services (ART) among mothers who did not continue ART after weaning19-36 months postpartumAverage time between delivery and discontinuation of ART among those mothers who did not continue ART
Heterogeneity of the impact of Option B+ on HIV-free survival among infants 9-18 months of age by the extent of integration of PMTCT and anti-retroviral therapy (ART) services at health facilitiesBaselineHIV-free survival in health facility catchment areas stratified by the extent of integration of PMTCT and ART services at the health facility
Heterogeneity of the impact of Option B+ on mother-to-child transmission of HIV (MTCT) among infants 9-18 months of age by the extent of integration of PMTCT and anti-retroviral therapy (ART) services at health facilitiesBaselineMTCT in health facility catchment areas stratified by the extent of integration of PMTCT and ART services at the health facility
Cost-effectiveness of Option B+ compared to the standard of care before Option ABaselineFacility costing data and HIV-free survival and MTCT in health facility catchment areas in 2012 compared to 2017
Cost-effectiveness of Option B+ compared to Option ABaselineFacility costing data and HIV-free survival and MTCT in health facility catchment areas in 2012 compared to 2014
Variability in health facility accesibilityBaselineAccessibility of health facilities assessed using exit interviews with patients receiving care at health facilities
Variability in health facility quality of available servicesBaselineQuality of available services at health facilities assessed using exit interviews with patients receiving care at health facilities, and clinical vignettes and time and motion studies with healthcare providers at health facilities
Variability in health facility appropriateness of available servicesBaselineAppropriateness of available HIV testing and counseling (HTC), prevention of mother-to-child transmission of HIV (PMTCT) and male circumcision (MC) services assessed using clinical vignettes with healthcare providers at health facilities

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026